Complex “Cross Talk” Involving Nitric Oxide Metabolites: Who’s Listening? David P. HajjarRuba S. DeebRita K. Upmacis Invited Commentary Pages: 347 - 348
Fibrate therapy in patients with metabolic syndrome and diabetes mellitus Thomas DayspringGregory Pokrywka OriginalPaper Pages: 356 - 364
Apolipoprotein A-I and risk for cardiovascular diseases Natalie KhuseyinovaWolfgang Koenig OriginalPaper Pages: 365 - 373
Lipoprotein-associated phospholipase A2: Pathogenic mechanisms and clinical utility for predicting cardiovascular events Vijay NambiChristie M. Ballantyne OriginalPaper Pages: 374 - 381
Are lower levels of low-density lipoprotein cholesterol beneficial? A review of recent data Anders G. Olsson ReviewPaper Pages: 382 - 389
Statins and the primary prevention of cardiovascular events Michael Clearfield OriginalPaper Pages: 390 - 396
Impact of thiazolidenediones on serum lipoprotein levels Ronald B. Goldberg OriginalPaper Pages: 397 - 404
High-density lipoprotein: Is it always atheroprotective? Benjamin J. AnsellGregg C. FonarowAlan M. Fogelman OriginalPaper Pages: 405 - 411
Clinical insights into the diagnosis and management of atherosclerotic renal artery disease Michael J. BlochJan Basile OriginalPaper Pages: 412 - 420
C-reactive protein and cardiovascular disease: Weighing the evidence Gordon D. O. LoweMark B. Pepys OriginalPaper Pages: 421 - 428
The CARDS trial: Diabetic patients dealt a winning hand Annemarie ArmaniPeter P. Toth OriginalPaper Pages: 429 - 432
Hypoadiponectinemia: A common basis for diseases associated with overnutrition Tohru FunahashiYuji Matsuzawa OriginalPaper Pages: 433 - 438